miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma
Autor: | Bin Qiu, Changfei Yuan, Hongmei Yang, Weiwei Han, Guanghua Xu, Rulin Sun, Yan Zhao, Lin Bao, Santao Zhang, Hangchuan Shi, Hailong Ruan, Anming Ruan, Xiaoping Zhang, Ning Lou, Yu-chen Xu |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
0301 basic medicine Pathology medicine.medical_specialty Angiomyolipoma Urology Kidney Nephrectomy 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma microRNA Biomarkers Tumor medicine Humans Carcinoma Renal Cell Neoplasm Staging Oligonucleotide Array Sequence Analysis Reverse Transcriptase Polymerase Chain Reaction business.industry Area under the curve Middle Aged medicine.disease Kidney Neoplasms Up-Regulation Reverse transcription polymerase chain reaction MicroRNAs Clear cell renal cell carcinoma 030104 developmental biology medicine.anatomical_structure ROC Curve Oncology Area Under Curve 030220 oncology & carcinogenesis Cancer research Biomarker (medicine) Female business |
Zdroj: | Urologic Oncology: Seminars and Original Investigations. 35:36.e7-36.e14 |
ISSN: | 1078-1439 |
DOI: | 10.1016/j.urolonc.2016.07.012 |
Popis: | Objectives Clear cell renal cell carcinoma (ccRCC) is the most frequent and lethal subtype of renal cell carcinoma, whose most effective measure of curing remains diagnosis and nephrectomy in its early phase. However, there is no feasible and recognized plasma biomarker for the clinical diagnosis of ccRCC. The objective of this study is to identify a novel plasma microRNA (miRNA) acting as an efficient diagnostic plasma biomarker in ccRCC. Methods and materials The plasma miRNA expression profile was quantified by miRNA microarray. Validation of miRNA levels of plasmas and tissues were performed by quantitative reverse transcription polymerase chain reaction in 106 ccRCC, 28 renal angiomyolipomas (AML), and 123 healthy control plasmas and in 110 ccRCC tissues. Results We found that plasma miR-144-3p levels in 106 ccRCC plasmas were remarkably up-regulated compared with that in healthy individuals and in patients with AML. miR-144-3p served as a promising plasma biomarker for yielding an area under the receiver operating characteristic curve of 0.91 with 87.10% sensitivity and 83.02% specificity in discriminating ccRCC from healthy individuals, and an area under the curve of 0.82 with 75.00% sensitivity and 71.70% specificity in discriminating ccRCC from patients with AML. In addition, plasma miR-144-3p levels were significantly decreased after surgery in 106 patients with ccRCC. Next, we examined miR-144-3p levels in 110 human ccRCC tissues, and found that miR-144-3p levels in ccRCC tissues were increased compared with adjacent normal tissues. Pearson correlation analysis revealed that miR-144-3p levels in tumor tissues were positively correlated with preoperative plasma miR-144-3p levels in the matched samples from patients with ccRCC. In addition, the miR-144-3p levels in ccRCC plasmas and tissues were increased in patients with advanced pT stage. Conclusions Our data indicate that miR-144-3p, which is significantly up-regulated in ccRCC plasmas and tissues, particularly with advanced pT stage, is a novel and excellent plasma biomarker for the diagnosis of ccRCC. |
Databáze: | OpenAIRE |
Externí odkaz: |